Home » Stocks » ImmunoGen

ImmunoGen, Inc. (IMGN)

Stock Price: $3.82 USD -0.04 (-1.04%)
Updated Aug 13, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 666.75M
Revenue (ttm) 86.46M
Net Income (ttm) -70.32M
Shares Out 174.54M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $3.82
Previous Close $3.86
Change ($) -0.04
Change (%) -1.04%
Day's Open 3.84
Day's Range 3.76 - 3.85
Day's Volume 1,401,996
52-Week Range 1.95 - 7.07

More Stats

Market Cap 666.75M
Enterprise Value 472.66M
Earnings Date (est) Oct 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 174.54M
Float 145.50M
EPS (basic) -0.42
EPS (diluted) -0.44
FCF / Share -0.69
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 16.48M
Short Ratio 7.66
Short % of Float 11.42%
Beta 2.34
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.71
PB Ratio n/a
Revenue 86.46M
Operating Income -51.64M
Net Income -70.32M
Free Cash Flow -120.86M
Net Cash 194.09M
Net Cash / Share 1.11
Gross Margin -37.30%
Operating Margin -59.73%
Profit Margin -81.30%
FCF Margin -139.79%
ROA -10.90%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 5
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(82.20% upside)
Current: $3.82
Target: 6.96
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth53.93%-53.71%92.41%-29.86%42.82%68.55%117.25%-15.27%38.46%-
Gross Profit82.2753.4511560.0085.5459.9035.5416.3619.3113.94
Operating Income-92.17-161-58.98-125-54.46-71.53-73.01-73.26-60.19-51.24
Net Income-104-169-96.01-145-60.74-71.36-72.81-73.32-58.27-50.91
Shares Outstanding14814098.0786.9886.0485.4884.0676.8168.9258.85
Earnings Per Share-0.70-1.21-0.98-1.67-0.71-0.83-0.87-0.95-0.85-0.87
Operating Cash Flow-88.37-1667.65-124-55.29-53.65-60.30-34.29-7.99-40.58
Capital Expenditures-0.53-5.25-1.12-10.38-7.43-8.18-3.77-2.91-2.03-1.53
Free Cash Flow-88.90-1726.53-135-62.72-61.83-64.07-37.20-10.02-42.12
Cash & Equivalents176262267245278142195161192111
Total Debt26.852.062.0596.63------
Net Cash / Debt149260265148278142195161192111
Book Value-76.1210.97-17.90-82.3035.1075.7012283.89140102
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ImmunoGen, Inc.
Country United States
Employees 75
CEO Mark J. Enyedy

Stock Information

Ticker Symbol IMGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMGN
IPO Date November 16, 1989


ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.